[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Danish Research Centre for Magnetic Resonance\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":241},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,52,84,112,151,182,209],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100623495","prtms-as-an-intervention-for-bradykinesia-in-parkinsons-disease-100623495",false,"NCT07397377","prTMS as an Intervention for Bradykinesia in Parkinson's Disease","Enhancing rTMS Effects Through a State-Dependent Approach - An Intervention for Bradykinesia in Parkinson's Disease","ADAPT-BK","Inclusion Criteria:\n\nAbove 18 years of age. Clinically established or probable Parkinson's Disease (PD), according to the Movement Disorder Society.\n\nClinical Diagnostic Criteria for PD. Stable antiparkinsonian medicine for at least four weeks. Signed informed consent.\n\nExclusion Criteria:\n\nPsychiatric disorders. Current use of antipsychotic medication, Donepezil, or GABAergic agents (e.g., pregabalin, gabapentin).\n\nFrequent benzodiazepine or opioid use defined as more than once per week on a regular basis.\n\nHistory of neurological disease other than PD. Past or present mental illness. History of epilepsy\u002Fconditions associated with increased risk of seizure induction through transcranial magnetic stimulation (TMS).\n\nClose relatives suffering from epilepsy\u002Fconditions associated with increased risk of seizures.\n\nContraindications for magnetic resonance imaging (MRI) Contraindications for TMS Female participants of childbearing age must not be pregnant and must use contraception during the trial.\n\nRefuse to be informed about new health-related information and accidental health-related findings that might appear through participation in the study.","ALL","18 Years","80 Years",{"count":21,"type":22},27,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study investigates the use of patterned repetitive transcranial magnetic stimulation (prTMS) as an intervention for bradykinesia in Parkinson's Disease (PD). More specifically, the study aims to determine whether prTMS over the supplementary motor area (SMA) can reduce severity of bradykinesia in PD patients. This approach may open for more targeted and effective treatment of bradykinesia in PD.",[28,29],"Bradykinesia","Parkinson Disease",[28,31,32,33,34,35,36,37,38],"Basal Ganglia Diseases","Parkinson's Disease","Central Nervous System Diseases","Movement Disorders","Synucleinopathies","Neurodegenerative Diseases","SMA","TMS","RECRUITING","2026-02-04",{"date":42,"type":43},"2026-02-09","ACTUAL",{"date":45,"type":43},"2025-12-16",{"date":47,"type":22},"2027-05-01",{"name":49,"class":50},"Danish Research Centre for Magnetic Resonance","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":51},"100623922","optimistic-and-pessimistic-dopamine-signals-in-the-human-brain-a-mapping-and-modelling-study-in-health-and-parkinsons-disease-100623922","NCT07402928","Optimistic and Pessimistic Dopamine Signals in the Human Brain: a Mapping and Modelling Study in Health and Parkinson's Disease","OPD","PD PATIENTS:\n\nInclusion Criteria:\n\n* At least 35 years of age.\n* Clinically established or probable PD according to the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease\n* Akinetic-rigid type PD\n* Stable antiparkinsonian medicine for 4 weeks without major side effects such as dyskinesia or on-off periods.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Female participants of childbearing age must not be pregnant, and they must use contraception.\n* Breastfeeding.\n* History of other neurologic or psychiatric disease other than depression.\n* Claustrophobia, pacemakers, implanted electronic devices, metal in the body, or other contraindications for MR scans.\n* Patients receiving advanced PD treatment such as duodopa pump or apomorphine pen\n* Regular intake of antipsychotics and GABAergic medications (such as pregabalin and gabapentine).\n* Severe depression (MDI score \\> 29).\n* Refuse to be informed about new health-related findings that might appear through participation.\n\nHEALTHY CONTROLS:\n\nInclusion criteria:\n\n* At least 35 years of age.\n* Signed informed consent.\n\nExclusion criteria:\n\n* Female participants of childbearing age must not be pregnant, and they must use contraception.\n* Breastfeeding.\n* History of neurologic or psychiatric disease other than depression.\n* Claustrophobia, pacemakers, implanted electronic devices, metal in the body, or other contraindications for MR scans.\n* Regular intake of antipsychotics and GABAergic medications (such as pregabalin and gabapentine).\n* Severe depression (MDI score \\> 29).\n* Refuse to be informed about new health-related information and accidental health-related findings that might appear through participation.",true,"35 Years",{"count":62,"type":22},140,"OBSERVATIONAL","The goal of this observational study is to investigate whether the healthy human brain shows a diversity of optimistic and pessimistic reward signals and whether changes in this distribution in Parkinson's disease (PD) can provide mechanistic insights into the cause of symptoms.\n\nThe main hypotheses it aims to test are:\n\n1. As shown in mice, a diversity of optimistic and pessimistic dopamine reward signals exists in the human ventral tegmental area (VTA) and the ventro-rostral basal ganglia circuit.\n2. Pessimistic neurons are more severely affected by neurodegeneration in PD.\n\nResearchers will compare the diversity of optimistic and pessimistic dopamine reward signals in patients with PD and healthy participants to see if there is a skewed distribution of optimistic and pessimistic reward signals in PD. Participants will play a task probing reward- and movement related brain activity in an MRI scanner. Researchers will derive functional topographic maps of optimism\u002Fpessimism in VTA, substantia nigra pars compacta (SNc), striatum and cortical areas such as the anterior cingulate cortex (ACC).\n\nIn sub-study 1, participants will be tested on one study day where patients with PD are tested in the off-medication state (40 control participants, 40 patients with PD).\n\nIn sub-study 2, to test whether\u002Fhow dopaminergic medication affects the distribution of optimism\u002Fpessimism, participants will be tested on two study days (30 control participants, 30 patients with PD). Patients with PD are tested one day in the off-medication state, another day in the on-medication state (order counterbalanced between patients with PD). Control participants are tested on two days without medication challenge to test for test-retest effects.",[66,67,68],"Healthy","Parkinson","Medication Administration",[70,71,72,73,74,75,76],"dopamine","reinforcement learning","distributional reinforcement learning","reward prediction error","reward","fMRI","parkinson",{"date":78,"type":43},"2026-02-11",{"date":80,"type":43},"2025-06-02",{"date":82,"type":22},"2027-06-30",{"name":49,"class":50},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":51},"100559854","fatigue-alleviation-through-neuromodulating-therapy-in-multiple-sclerosis-100559854","NCT06569550","Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis","Neuromodulation of the Left Premotor Cortex With Transcranial Magnetic Stimulation to Alleviate Fatigue in Multiple Sclerosis - a Randomised Controlled Clinical Trial","FANTiMS","Inclusion Criteria:\n\n* A confirmed diagnosis of relapse-remitting or secondary progressive multiple sclerosis, according to most recent McDonald's criteria (Thompson et al., 2018). This diagnosis must not be more recent than 3 months\n* Must have fatigue as a complaint, and an FSMC score corresponding to at least moderate fatigue (\\>53)\n* Stable MS medication for at least 3 months\n\nExclusion Criteria:\n\n* Pregnancy, any subject with the potential to become pregnant must ensure against this (e.g. by taking oral contraceptives, or other high efficacy method)\n* MS Relapse or steroid treatment within 3 months prior to inclusion\n* Current treatment targeted towards fatigue, or previous if discontinued within 3 months prior to inclusion\n* History of neurologic disease or other significant medical conditions, aside from MS\n* EDSS \\> 6.5\n* Major psychiatric disorder, including current clinical depression.\n* Intake of medication that primarily acts on CNS or neurotransmission, except SSRI or SNRI\n* Pacemaker or other implanted electronic devices\n* Any intracranial metal\n* Any metallic implant incompatible with MR scanning\n* Claustrophobia\n* Either patient or their close relatives suffering from epilepsy\n* Current Drug or alcohol abuse","65 Years",{"count":94,"type":22},60,[25],"The goal of this clinical trial is to learn if repetitive Transcranial Magnetic Stimulation (rTMS) of the left premotor cortex can lessen fatigue in patients with Multiple Sclerosis, and if this is a feasible intervention. It will also give further information on fatigue in Multiple Sclerosis. The main questions it aims to answer is:\n\n* Does premotor rTMS decrease fatigue symptoms in patients with Multiple Sclerosis?\n* Is the change in fatigue reflected in an altered balance between brain excitation and inhibition in the targeted premotor cortex?\n\nResearchers will compare real rTMS with sham rTMS (which does not stimulate with a magnetic field), to see if real rTMS works to alleviate fatigue.\n\nParticipants will:\n\n* Receive real or sham rTMS for 30 minutes, 5 days in a row\n* Visit the clinic before and 6 days after for baseline and follow-up\n* Fill out on-line questionnaires 1 day and 4 weeks after the end of intervention\n* Undergo a total of 3 brain scans (Magnetic Resonance Imaging at ultra-high field), at baseline, end of intervention, and follow-up\n* Undergo lab neurophysiological measurements before and after the first intervention session\n* Keep a fatigue diary and wear an activity tracker in the period before and after the intervention",[98,99],"Multiple Sclerosis, Relapsing-Remitting","Fatigue",[101,102,103],"Transcranial Magnetic Stimulation, Repetitive","Magnetic Resonance Imaging","Magnetic Resonance Imaging, Spectroscopy","2026-01-27",{"date":106,"type":43},"2026-01-28",{"date":108,"type":43},"2024-08-14",{"date":110,"type":22},"2026-11-01",{"name":49,"class":50},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":59,"sex":17,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":123,"conditions":124,"keywords":128,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":51},"100546559","neuroimaging-of-babies-during-natural-sleep-to-assess-typical-development-and-cerebral-palsy-100546559","NCT06396520","Neuroimaging of Babies During Natural Sleep to Assess Typical Development and Cerebral Palsy","NIBS-CP","Inclusion Criteria High-Risk population:\n\nGroup: 'Newborn-detectable risk-pathway'\n\n* Preterm birth with gestational age below 32 weeks\n* Birth weight below 1500 g\n* Moderate to severe brain injury (A label of moderate to severe brain injury was considered if there was Papile grade three to four intraventricular haemorrhage, cystic periventricular leukomalacia, neonatal stroke, term hypoxic-ischaemic encephalopathy (≥35 weeks gestation at birth) or other significant neurological condition)\n* History (e.g., neonatal seizures, ECMO, meningitis, kernicterus, severe hypoglycemia) or neurological risk factors (malformations in CNS, increased tone)\n\nGroup: 'Infant detectable risk-pathway'\n\n* Inability to sit independently by age 9 months\n* Hand function asymmetry or crawl asymmetry\n* Inability to take weight through the plantar surface of the feet\n* History (e.g., as above) or neurological risk factors\n\nAdditional inclusion criteria for inclusion in NIBS-CP for both CP-risk groups:\n\n\\- Consent to health-relevant information on clinical findings being passed on to the medical doctors in CP-EDIT and\u002For their primary care physician.\n\nInclusion Criteria Typically developing infant population:\n\n* Born \\>37 weeks\n* Uneventful birth\n* No known history of brain injury\n* No neurological condition\n* Consent to health-relevant information on clinical findings being passed on to their primary care physician or relevant medical doctors, e.g., neuropaediatrician.\n\nExclusion Criteria (all groups):\n\n* Infants have any MRI contraindications, e.g., pacemaker or other implanted electronic devices.\n* Families do not speak or understand Danish.\n* Families do not wish to be informed about incidental findings on the MRI, or scores within the clinical range in the neurological, motor, or cognitive assessments.","2 Months","11 Months",{"count":122,"type":22},200,"Background: Early diagnosis of cerebral palsy (CP) is crucial, enabling intervention when neuroplasticity is at its highest. Magnetic resonance imaging (MRI) plays a vital role in CP diagnosis. Currently, diagnostic MRI of newborns and infants with suspected brain damage relies heavily on structural MR images. The current study aims to i) establish procedures for clinical infant and toddler MRI during natural sleep, ii) use advanced MRI sequences, such as advanced diffusion-weighted imaging (DWI), that may be more sensitive in detecting early brain damage, and iii) map relationships between early brain development, and motor function and development.\n\nMethods: The NIBS-CP study will enroll approximately 200 infants either at risk for CP or typically developing. Infants will be followed longitudinally (for three waves) between 3 months and 2 years of age with cerebral MRI at 3 Tesla and comprehensive assessments of motor and cognitive functioning. The MRI protocol includes advanced diffusion-weighted imaging, high-resolution structural MRI, and MR spectroscopy. The motor and cognitive assessments include Hand Assessment in Infants, Alberta Infant Motor Scales, Hammersmith Infant Neurological Examination, Peabody Developmental Motor Scales, Bayley Scales of Infant Development, and Ages and Stages Questionnaires. NIBS-CP aims to establish normative material on early brain development of Danish children and conduct normative modeling of typical and atypical development to identify deviations in brain development at the level of the single child.\n\nDiscussion: Identifying predictive brain structural features of motor function and motor development is key to the future use of early MRI in the clinical work-up, as this promotes early diagnosis and (clinical) intervention strategies tailored to the individual child.",[125,126,127],"Cerebral Palsy","Infant Development","Development, Infant",[129,130,131,132,133,134,135,136,137,125,138,139,140,141,142,143,144],"MRI","Brain development","Diffusion MRI","Motor development","Cognitive development","Normative modelling","Hand assessment for infants","Alberta Infant Motor scale","Motor functioning","Typically developing","Infants","Toddlers","Children","Peabody Developmental Motor Scales","Corticospinal tract","Motor system",{"date":106,"type":43},{"date":147,"type":43},"2024-06-01",{"date":149,"type":22},"2027-12-31",{"name":49,"class":50},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":181},"100584938","copenhagen-magnetic-personalized-accelerated-brain-circuit-therapy-for-treatment-resistant-depression-100584938","NCT06895863","COpenhagen Magnetic Personalized Accelerated Brain Circuit Therapy for Treatment Resistant Depression","The Copenhagen Magnetic Personalized Accelerated Brain Circuit Therapy (CoMPACT) Trial","CoMPACT","Inclusion criteria:\n\n* Age range between 18 and 95 years\n* In- or outpatients with a moderate to severe single episode or periodic MDD according to ICD-10, verified by a M.I.N.I. interview.\n* Major Depression Inventory (self-rapport) score higher than 25.\n* Lacking or insufficient effect of at least two drug trials from two distinct classes, e.g., SSRI, SNRI, TCA, or MAO-inhibitors, used in the current episode, with adequate dose and duration as judged by the investigator.\n* Duration of the current episode must be longer than 2 months but shorter than 4 years, as judged by the investigator.\n\nExclusion criteria:\n\n* History of neurologic disease affecting the brain, including dementia and epilepsy\n* Schizophrenia or any other psychotic disorder except for psychotic depression\n* Head trauma causing more than 5 minutes loss of consciousness\n* Suicidal or psychotic symptoms making the transport of participants hazardous\n* Any form of compulsory admission or treatment within the past three months\n* Treatment with ECT in the current depressive episode\n* Non-responders to TBS treatment within the current episode\n* Current harmful use or dependency of substances according to ICD-10 and interfering with outcome evaluation as judged by investigator's discretion.\n* High risk of non-adherence as judged by investigators discretion\n* Medical and psychiatric conditions interfering with study outcome and safety as judged by investigator's discretion.\n* Female participants of childbearing age must not be pregnant or breast feeding, and they must use contraception during the trial.\n* One of the prime contra-indications for MRI, including severe claustrophobia (see Appendix 08.05)\n* One of the prime contra-indications for TMS and persons with electrically, magnetically, or mechanically activated implants or with metal or magnetic pieces in their head (see Appendix 08.04)\n* Patients who do not wish to be informed about MRI or EEG findings, which may have clinical relevance.","95 Years",{"count":161,"type":22},78,[25],"The CoMPACT trial is a randomized double-blinded sham-controlled study aimed at testing a novel accelerated and personalized transcranial Magnetic Stimulation (TMS) treatment for patients with Treatment Resistant Depression (TRD).\n\nCoMPACT consists of 25 sessions of intermittent theta-burst transcranial stimulation (iTBS) consisting of high inter-pulse frequency administered five times daily over five consecutive days.\n\nThe trial will include 78 patients with TRD who will be randomly assigned to one of three groups:\n\n* Group 1: Real CoMPACT targeting the left dorsolateral prefrontal cortex (DLPFC).\n* Group 2: Real CoMPACT targeting a novel site, the left inferior parietal lobule (IPL).\n* Group 3: Sham CoMPACT targeting the left DLPFC (50%, Group 3a) or left IPL (50%, Group 3b).\n\nThe hypothesis is that real prefrontal or parietal CoMPACT targeting will significantly alleviate depression symptoms compared to sham targeting, without compromising safety, feasibility, or tolerability.\n\nThe trial incorporates a personalized approach, using electrical field (E-field) modeling based on individual structural brain scans to tailor and standardize iTBS, ensuring accurate targeting of cortical volume and consistent induced electrical field strength. To delineate the treatment mechanism of action at the brain network level, multi brain mapping models will be implemented. Electroencephalography (EEG) records of spontaneous and TMS-evoked electrical brain activity will be obtained before, during, and after iTBS sessions to understand how the high frequency burst protocol functionally engages the stimulated cortex. Structural and functional brain MRI before and after the treatment will be used to study changes in depression-related brain networks. This will offer key insights into how CoMPACT affects depression-related brain networks and may identify neuroimaging markers for predicting treatment response, and thus informing future TBS treatments for TRD.",[165],"Treatment Resistant Depression",[167,168,169,170,171,172],"Brain circuit therapy","Major depressive disorder (MDD)","Transcranial magnetic stimulation (TMS)","Intermittent theta burst stimulation (iTBS)","Copenhagen Magnetic Personalized Accelerated Brain Circuit Therapy (COMPACT)","Treatment resistant depression (TRD)","2026-01-20",{"date":175,"type":43},"2026-01-22",{"date":177,"type":43},"2025-01-15",{"date":179,"type":22},"2028-09-01",{"name":49,"class":50},3,{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":208,"locationsCount":51},"100559952","rtms-as-an-intervention-for-levodopa-induced-dyskinesia-100559952","NCT06570824","rTMS as an Intervention for Levodopa-induced Dyskinesia","Network Based Repetitive Transcranial Magnetic Stimulation (rTMS) as an Intervention for Levodopa-induced Dyskinesia (LID) in Parkinson's Disease (PD)","ADAPT-LIDI","Inclusion Criteria:\n\n* Clinically established or probable PD\n* Clinical Diagnostic Criteria for Parkinson's Disease\n* Peak-of-dose levodopa-induced dyskinesia.\n* Stable antiparkinsonian medicine for at least four weeks.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Psychiatric disorders.\n* Usage of antipsychotic medication, Donepezil, and GABAergic medications (such as pregabalin and gabapentin).\n* Regular usage of benzodiazepines and opioids (more than once per week).\n* History of neurological disease other than Parkinson's disease.\n* History of epilepsy\u002Fconditions associated with increased risk to seizure-induction through TMS.\n* Close relatives suffering from epilepsy\u002Fconditions associated with increased risk to seizure-induction through TMS.\n* Contraindications for MRI scan\n* Female participants of childbearing age must not be pregnant and that they must use contraception during the trial.\n* Refuse to be informed about new health related information and accidental health related findings that might appear through participation in the study.",{"count":191,"type":22},68,[25],"The proposed study investigates the use of repetitive transcranial magnetic stimulation (rTMS) as a treatment for levodopa-induced dyskinesia (LID) in Parkinson's Disease (PD). Specifically, the study aims to determine whether patterned stimulation of the pre-supplementary motor area (pre-SMA) can delay the onset of LID after levodopa intake and reduce LID severity in PD patients. This study will provide critical insights into potential targets for rTMS treatment, optimal rTMS parameters, and the mechanisms underlying LID in Parkinson's disease.",[195,29],"Dyskinesia, Drug-Induced",[31,197,33,34,35,36,198,199,200,201],"Parkinson's Disease","Dyskinesias","LID","Levodopa induced dyskinesia","Pre-SMA","2024-08-26",{"date":204,"type":43},"2024-08-28",{"date":206,"type":43},"2024-07-22",{"date":47,"type":22},{"name":49,"class":50},{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":59,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":218,"conditions":219,"keywords":222,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":240},"100371623","microstructure-imaging-in-stroke-patients-100371623","NCT04118790","Microstructure Imaging in Stroke Patients","New Clinical Magnetic Resonance Technologies for Capturing Brain Microstructure Alterations in Patients With Minor Stroke or Transient Ischemic Attack","Patient Inclusion Criteria:\n\n* Stroke or TIA (ABCD2\\>4 and\u002For acute Diffusion-Weighted Image (DWI) lesion).\n* Modified Rankin Scale \\\u003C=2.\n* As perceived by the investigator, have the ability to comply with all requirements of the study protocol.\n* Have the ability to understand and sign the Informed Consents Form.\n* Multidimensional Fatigue Inventory score \\>= 12 on general fatigue.\n\nPatient Exclusion Criteria:\n\n* The DRCMR´s general exclusion criteria for MRI research.\n* Pregnancy or lactation; human chorionic gonadotropin (hCG) urine test is offered for women \\\u003C 55 years.\n* Major medical illness (for instance: anemia, diabetes mellitus, thyroid disorders, cardiovascular disease, electrolyte imbalance, etc.)\n* Treated with ritalin or modafinil.\n* Known uncontrolled severe malignancy.\n* Known drug or alcohol addiction.\n* Tiredness due to pharmaceutical side effects, as identified by the Investigator.\n* Max body weight of 130 kg.\n* Persons who do not wish to be informed about abnormal findings as part of the investigations.\n\nHealthy Controls Exclusion Criteria:\n\n* The DRCMR´s general exclusion criteria for MRI research.\n* Pregnancy or lactation; urin hCG test is offered for women \\\u003C 55 years.\n* Major medical illness (for instance: anemia, diabetes mellitus, thyroid disorders, cardiovascular disease, electrolyte imbalance, etc.)\n* Anamnestic infection (cystitis, influenza, pneumonia, etc) the last 3 weeks.\n* Known malignancy.\n* Known drug or alcohol addiction.\n* Tiredness due to pharmaceutical side effects.\n* Max body weight of 130 kg.\n* Persons who do not wish to be informed about abnormal findings as part of the investigations.\n\nHealthy Controls Inclusion Criteria:\n\n* Healthy\n* Age- and sex-matched to patient groups.\n* As perceived by the investigator, have the ability to comply with all requirements of the study protocol.\n* Have the ability to understand and sign the Informed Consents Form.",{"count":217,"type":22},90,"The purpose of this study is to establish a methodological framework based on existing advanced neuroimaging technologies as a new clinical neuroimaging tool for assessment of possible affected brain connections in stroke and TIA patients. Thus, providing new insights into microstructural changes that may underline why those patients experience deficits like fatigue.",[99,220,221],"Stroke, Acute","Transient Ischemic Attack",[99,223,224,225,129,226,227,228,229,230,231],"minor stroke","TIA","Diffusion","Quantitative","Sequence","Microstructure","Axon","Myelin","Degeneration","2022-05-25",{"date":234,"type":43},"2022-05-26",{"date":236,"type":43},"2019-12-23",{"date":238,"type":22},"2029-03-01",{"name":49,"class":50},2,""]